Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A... IntroductionThe effectiveness of telmisartan has been reported in Indian clinical trials; however, real-world data are limited. We aimed to provide real-world evidence regarding the effectiveness of telmisartan as monotherapy or in combination with other antihypertensive drugs (AHDs) in Indian patients with essential hypertension.MethodsElectronic medical record data of adult patients diagnosed with essential hypertension (≥ 140/90 mmHg) and who were prescribed telmisartan as mono- or add-on therapy were retrospectively analyzed. Patients were classified according to the number of AHD classes prescribed on initiating telmisartan. Change in systolic and diastolic blood pressure (SBP and DBP) after a month of treatment and the proportion of patients who achieved treatment goals according to the 2018 European Society of Cardiology/European Society of Hypertension guidelines were evaluated.ResultsA majority (90.6%) of the 1304 patients included in the study were on telmisartan monotherapy or telmisartan + 1 AHD. The mean (95% confidence interval [CI]) change in the telmisartan monotherapy group was SBP (−13.3 [−14.6, −12.0] mmHg) and DBP (−7.2 [−7.9, −6.5] mmHg), and the mean (95% CI) change in the telmisartan + 1 AHD group was SBP (−10.8 [−13.1, −8.5] mmHg) and DBP (−6.5 [−7.7, −5.3] mmHg) (P < 0.001 for all). SBP and DBP goals were achieved by 35.9% and 47.3% of patients on telmisartan monotherapy and by 35.9% and 46.8% of patients on telmisartan + 1 AHD. Among patients with comorbid diabetes, the mean (95% CI) change in the telmisartan monotherapy group was SBP (−13.3 [−15.0, −11.6] mmHg) and DBP (−7.3 [-8.2, −6.5] mmHg), and the mean (95% CI) change in the telmisartan + 1 AHD group was SBP (−13.0 [−16.5, −9.5] mmHg) and DBP (−6.9 [−8.7, −5.1] mmHg) (P < 0.001 for all). SBP and DBP goals were achieved by 31.7% and 39.7% of patients on telmisartan monotherapy and by 31.9% and 41.8% of patients on telmisartan + 1 AHD.ConclusionTelmisartan may be a good candidate for blood pressure control in Indian patients with essential hypertension and comorbidities. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records

Loading next page...
 
/lp/springer-journals/effectiveness-of-telmisartan-on-blood-pressure-control-in-hypertensive-rSqbk0Duyq

References (48)

Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-021-00217-7
Publisher site
See Article on Publisher Site

Abstract

IntroductionThe effectiveness of telmisartan has been reported in Indian clinical trials; however, real-world data are limited. We aimed to provide real-world evidence regarding the effectiveness of telmisartan as monotherapy or in combination with other antihypertensive drugs (AHDs) in Indian patients with essential hypertension.MethodsElectronic medical record data of adult patients diagnosed with essential hypertension (≥ 140/90 mmHg) and who were prescribed telmisartan as mono- or add-on therapy were retrospectively analyzed. Patients were classified according to the number of AHD classes prescribed on initiating telmisartan. Change in systolic and diastolic blood pressure (SBP and DBP) after a month of treatment and the proportion of patients who achieved treatment goals according to the 2018 European Society of Cardiology/European Society of Hypertension guidelines were evaluated.ResultsA majority (90.6%) of the 1304 patients included in the study were on telmisartan monotherapy or telmisartan + 1 AHD. The mean (95% confidence interval [CI]) change in the telmisartan monotherapy group was SBP (−13.3 [−14.6, −12.0] mmHg) and DBP (−7.2 [−7.9, −6.5] mmHg), and the mean (95% CI) change in the telmisartan + 1 AHD group was SBP (−10.8 [−13.1, −8.5] mmHg) and DBP (−6.5 [−7.7, −5.3] mmHg) (P < 0.001 for all). SBP and DBP goals were achieved by 35.9% and 47.3% of patients on telmisartan monotherapy and by 35.9% and 46.8% of patients on telmisartan + 1 AHD. Among patients with comorbid diabetes, the mean (95% CI) change in the telmisartan monotherapy group was SBP (−13.3 [−15.0, −11.6] mmHg) and DBP (−7.3 [-8.2, −6.5] mmHg), and the mean (95% CI) change in the telmisartan + 1 AHD group was SBP (−13.0 [−16.5, −9.5] mmHg) and DBP (−6.9 [−8.7, −5.1] mmHg) (P < 0.001 for all). SBP and DBP goals were achieved by 31.7% and 39.7% of patients on telmisartan monotherapy and by 31.9% and 41.8% of patients on telmisartan + 1 AHD.ConclusionTelmisartan may be a good candidate for blood pressure control in Indian patients with essential hypertension and comorbidities.

Journal

Cardiology and TherapySpringer Journals

Published: Apr 8, 2021

There are no references for this article.